IKNA - Why Is Cancer Firm Ikena Oncology Stock Trading Lower Today? | Benzinga
Ikena Oncology Inc (NASDAQ: IKNA) shared initial data from twenty-six patients treated in the ongoing dose escalation portion of the Phase 1 trial of IK-930.
IK-930 selectively binds TEAD1 and broadly represses oncogenic TEAD signaling as a potent Hippo-pathway inhibitor, a known suppressor pathway in cancers such as epithelioid hemangioendothelioma (EHE), mesothelioma, meningioma, and others.
26 patients have been treated with IK-930 in dose escalation as of ...